Background: Two-drug regimens are increasingly used in clinical practice as switch strategies. We compared the efficacy and safety of two dolutegravir-based dual therapies (DT): dolutegravir plus lamivudine (3TC group) versus DTG plus rilpivirine (RPV group). Methods: In a multicenter cohort of virologically suppressed (HIV-RNA <50 cp/ml) HIV+ pts switching to DTG+3TC or DTG+RPV we analyzed the incidence of virological failures (VF) and treatment discontinuations (TD), as well as their predictors. Results: We analyzed 416 pts, 229 in the 3TC group and 187 in the RPV group. The 3TC group, during 344.4 person-years of follow-up (PYFU), had 10 VF without the emergence of resistance mutations, while 30 pts discontinued the regimen. In the RPV group, during 371.0 PYFU, there were 5 VF (one developed NNRTI-mutations Y181C and E138Q) and 13 TD. The estimated probability of remaining free from VF at 48 weeks showed no significant difference between groups (log-rank 0.172). We found a higher risk of VF in patients with peak VL>500000cp/ml in both treatment groups (log-rank p=0.004 in each group). The estimated probability of remaining in the study regimen at week 48 was 89.0% with DTG+3TC and 96.1% with DTG+RPV (log-rank 0.015). After adjusting for potential confounders, treatment group was not associated to TD. A significant decrease in total cholesterol was observed at week 48 in both groups while renal function remained unchanged. Conclusions: DTG+RPV and DTG+3TC were compared in populations with different characteristics in clinical practice: both regimens showed good effectiveness and improved lipid profile. Background: Two-drug regimens are increasingly used in clinical practice as switch strategies. We compared the efficacy and safety of two dolutegravir (DTG)-based dual therapies: DTG plus lamivudine (3TC group) versus DTG plus rilpivirine (RPV group). Methods: In a multicentre cohort of virologically suppressed (HIV RNA <50 copies/ml) HIV+ patients switching to DTG+3TC or DTG+RPV we analysed the incidence of virological failures (VF) and treatment discontinuations (TD), as well as their predictors. Results: We analysed 416 patients, 229 in the 3TC group and 187 in the RPV group. The 3TC group, during 344.4 person-years of follow-up (PYFU), had 10 VF without the emergence of resistance mutations, while 30 patients discontinued the regimen. In the RPV group, during 371.0 PYFU, there were 5 VF (1 developed non-nucleoside reverse transcriptase inhibitor mutations Y181C and E138Q) and 13 TD. The estimated probability of remaining free from VF at 48 weeks showed no significant difference between groups (log-rank 0.172). We found a higher risk of VF in patients with peak viral load >500,000 copies/ml in both treatment groups (log-rank P=0.004 in each group). The estimated probability of remaining in the study regimen at week 48 was 89.0% with DTG+3TC and 96.1% with DTG+RPV (log-rank 0.015). After adjusting for potential confounders, treatment group was not associated with TD. A significant decrease in total cholesterol was observed at week 48 in both groups while renal function remained unchanged. Conclusions: DTG+RPV and DTG+3TC were compared in populations with different characteristics in clinical practice: both regimens showed good effectiveness and improved lipid profile.
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients / A. Ciccullo, G. Baldin, A. Capetti, S. Rusconi, G. Sterrantino, G. D'Ettorre, M. Colafigli, S. Modica, F. Lagi, A. Giacomelli, M. Cossu, S. Restelli, A. De Luca, S. Di Giambenedetto. - In: ANTIVIRAL THERAPY. - ISSN 1359-6535. - (2018 Oct 02). [Epub ahead of print] [10.3851/IMP3270]
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients
A. Capetti;S. Rusconi;A. Giacomelli;M.V. Cossu;
2018
Abstract
Background: Two-drug regimens are increasingly used in clinical practice as switch strategies. We compared the efficacy and safety of two dolutegravir-based dual therapies (DT): dolutegravir plus lamivudine (3TC group) versus DTG plus rilpivirine (RPV group). Methods: In a multicenter cohort of virologically suppressed (HIV-RNA <50 cp/ml) HIV+ pts switching to DTG+3TC or DTG+RPV we analyzed the incidence of virological failures (VF) and treatment discontinuations (TD), as well as their predictors. Results: We analyzed 416 pts, 229 in the 3TC group and 187 in the RPV group. The 3TC group, during 344.4 person-years of follow-up (PYFU), had 10 VF without the emergence of resistance mutations, while 30 pts discontinued the regimen. In the RPV group, during 371.0 PYFU, there were 5 VF (one developed NNRTI-mutations Y181C and E138Q) and 13 TD. The estimated probability of remaining free from VF at 48 weeks showed no significant difference between groups (log-rank 0.172). We found a higher risk of VF in patients with peak VL>500000cp/ml in both treatment groups (log-rank p=0.004 in each group). The estimated probability of remaining in the study regimen at week 48 was 89.0% with DTG+3TC and 96.1% with DTG+RPV (log-rank 0.015). After adjusting for potential confounders, treatment group was not associated to TD. A significant decrease in total cholesterol was observed at week 48 in both groups while renal function remained unchanged. Conclusions: DTG+RPV and DTG+3TC were compared in populations with different characteristics in clinical practice: both regimens showed good effectiveness and improved lipid profile. Background: Two-drug regimens are increasingly used in clinical practice as switch strategies. We compared the efficacy and safety of two dolutegravir (DTG)-based dual therapies: DTG plus lamivudine (3TC group) versus DTG plus rilpivirine (RPV group). Methods: In a multicentre cohort of virologically suppressed (HIV RNA <50 copies/ml) HIV+ patients switching to DTG+3TC or DTG+RPV we analysed the incidence of virological failures (VF) and treatment discontinuations (TD), as well as their predictors. Results: We analysed 416 patients, 229 in the 3TC group and 187 in the RPV group. The 3TC group, during 344.4 person-years of follow-up (PYFU), had 10 VF without the emergence of resistance mutations, while 30 patients discontinued the regimen. In the RPV group, during 371.0 PYFU, there were 5 VF (1 developed non-nucleoside reverse transcriptase inhibitor mutations Y181C and E138Q) and 13 TD. The estimated probability of remaining free from VF at 48 weeks showed no significant difference between groups (log-rank 0.172). We found a higher risk of VF in patients with peak viral load >500,000 copies/ml in both treatment groups (log-rank P=0.004 in each group). The estimated probability of remaining in the study regimen at week 48 was 89.0% with DTG+3TC and 96.1% with DTG+RPV (log-rank 0.015). After adjusting for potential confounders, treatment group was not associated with TD. A significant decrease in total cholesterol was observed at week 48 in both groups while renal function remained unchanged. Conclusions: DTG+RPV and DTG+3TC were compared in populations with different characteristics in clinical practice: both regimens showed good effectiveness and improved lipid profile.File | Dimensione | Formato | |
---|---|---|---|
AVT-18-SC-4413_Ciccullo_October 2, 2018.pdf
accesso riservato
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
338.7 kB
Formato
Adobe PDF
|
338.7 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
AVT-18-SC-4413_Ciccullo_AOP.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
120.56 kB
Formato
Adobe PDF
|
120.56 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.